Olivier Hermine
15Patents
2h-index
40Co-inventors
50Inventor score
Filing activity: Jun 28, 2002 → Sep 4, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7976841B2 | Anti TfR antibody | Chemistry; Metallurgy | 5 | Expired |
| US10151745B2 | Methods for determining the risk of acute graft versus host disease | Physics | 2 | Active |
| US9463217B1 | Methods and pharmaceutical compositions for treatment of retinal occlusion | Chemistry; Metallurgy | 1 | Active |
| US9377471B2 | Methods and compositions for the treatment of β-thalassemia | Physics | 1 | Active |
| US11389434B2 | Methods and pharmaceutical compositions for the treatment of mast cell diseases | Emerging Cross-Sectional Technologies | 0 | Active |
| US10647752B2 | Polypeptides capable of inhibiting the binding between leptin and Neuropilin-1 | Chemistry; Metallurgy | 0 | Active |
| US9107893B2 | Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma | Human Necessities | 0 | Active |
| US8784797B2 | Methods, pharmaceutical compositions and kits for use in the treatment of adult T-cell leukemia/lymphoma | Human Necessities | 0 | Active |
| US9675590B2 | Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromes | Human Necessities | 0 | Active |
| US9861615B2 | Methods and pharmaceutical compositions for the treatment of beta-thalassemias | Physics | 0 | Active |
| US7727731B2 | Potent, selective and non toxic c-kit inhibitors | Physics | 0 | Expired |
| US11065230B2 | Methods and pharmaceutical compositions for the treatment of systemic mastocytosis | Chemistry; Metallurgy | 0 | Active |
| US11629192B2 | Methods and pharmaceutical compositions for the treatment of diseases mediated by the NRP-1/OBR complex signaling pathway | Emerging Cross-Sectional Technologies | 0 | Active |
| US10111896B2 | Composition comprising a combination of DNA methylation inhibitor and a vitamin D receptor agonist for the treatment of drug resistant cancer or for the prevention of tumor relapse | Human Necessities | 0 | Active |
| US10617658B2 | Use of hydroxycarbamide for preventing retinal nonperfusion | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.